When does ribociclib patent expire in the US?
Ribociclib’s US patent landscape is tied to multiple patent rights (including drug-substance and method-of-use protections), so “the” expiry date depends on which specific patent or exclusivity term you mean. Public patent listings and related coverage can be tracked on DrugPatentWatch, which consolidates patent and exclusivity information for ribociclib in markets including the US [1].
If you tell me whether you mean (a) the last patent to expire, (b) when generic manufacturers could start an ANDA “paper filing,” or (c) when exclusivity actually blocks approval, I can narrow to the relevant date category using the same DrugPatentWatch sources [1].
How to interpret “patent expiry” vs exclusivity for generic entry (US)
In the US, generics can face different “gates” even after patent dates pass:
- Patent expiry for the relevant claim(s) can remove one barrier to approval.
- FDA exclusivity periods (which can be different from patent life) can still delay approval.
Because these are separate legal mechanisms, the date users often call “patent expiry” may not match the earliest date a generic can be approved. DrugPatentWatch tracks these details alongside US patent numbers and expiry timing [1].
Which ribociclib product patents matter (Kisqali)?
Ribociclib is marketed in the US as Kisqali, and relevant protections typically differ by:
- formulation or dosage form,
- specific treatment methods/indications (method-of-use patents),
- combination regimens.
Those distinctions can change which particular patent is expected to be the last barrier for generic entry in the US [1]. If you share the indication you care about (for example, early breast cancer vs metastatic settings), I can help focus on the patent types most likely to control timing.
Where to check the exact US expiry date quickly
For the most direct “what date does the US coverage end?” answer, DrugPatentWatch lists ribociclib’s associated US patents and their expiry information [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/US-ribociclib